Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 03, 2026 05:40 ET | Source: Hopstem Biotechnology Inc.

Hopstem hNPC01 Cell Injection Earns FDA RMAT Designation for Chronic Stroke Therapy

HOUSTON, June 03, 2026 (GLOBE NEWSWIRE) -- Hopstem Biotechnology, a clinical-stage biotech specializing in iPSC-derived cell therapeutics for neurological diseases, has secured the first...
January 21, 2026 02:46 ET | Source: Hopstem Biotechnology Inc.

FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging Study

FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging Study